Quote from: GCM on January 31, 2019, 11:43:15 PM

Global Cell Med is honored to be chosen as one of the first recipients of the EMC2 Foundations 2018 Award for Science.

Global Cell Med is the only treatment for type 1 diabetes that is government approved and scientifically proven through peer reviewed clinical trials. Our treatment has an 80% success rate to reverse diabetes, substantially or completely eliminating the need for artificial insulin or other diabetic drugs.

We would like the bitcointalk and EMC2 communities to help us spread the word about our diabetes treatment. Any diabetic that is referred to us will receive our treatment in Nassau, Bahamas, for less than half the current price. To obtain more details please contact Mike Sayre at mike@globalcellmed.com.

The 50,000 in EMC2 is very approciated,

Michael Sayre
Dr. Alejandro Mesples
Global Cell Med and Stem Cell Bahamas

Our Bittrex wallet is: ETQegYSfHPy8iDYPpPvyiSrNw8oi9gqLgB

Quote from: einsteinium on January 14, 2019, 01:24:07 PM

January 2019 - The Einsteinium Foundation (EMC2) is proud to announce the finalists for the first annual Einsteinium Awards. This year's winners are:

Minh Thang Harry Hoang - McGill University
Michael Sayre - Global Cell Med

The Einsteinium Awards celebrates innovative work across all areas of science. We aim to engage and foster a community devoted to scientific research as a long-term investment in our future and future of our planet.

The award is 100,000 EMC2 coins, which will be evenly split among our two winners. The EMC2 awards is funded directly by the EMC2 Foundation.

Dr. Thang Hoang has widely published, including six first author papers, his work as a PhD candidate in Electrical Engineering under Professor David V. Plants supervision in the Photonic Systems Group at McGill University. His cutting-edge work on a novel and effective self-coherent transceiver using Stokes Vector modulation may impact global information traffic and allow for faster data connections.

Michael Sayre is the CEO of Global Cell Med, a biotech company specializing in a regenerative medicine approach to treating diabetes. The company has published its therapeutic strategy and is currently conducting clinical trials on patients with chronic Type 1 Diabetes, with very promising early results.

Our first annual award attracted a global pool of applicants with equally diverse backgrounds. This included an applicant in the social sciences from Georgia State University and a stem cell biologist from the First Moscow State Medical University.
The inaugural class has set an amazing example on what community based and open science can be. We look forward to our applicant pool next year. Interested parties should contact: projects@emc2.foundation to find out more.

Despite the need for research and development to spur innovative solutions for a host of urgent problems. Unfortunately, in most countries, public commitments for scientific research have continued to fall. However, the Einsteinium Foundation hopes to play a part in reversing that trend. Blockchain based funding for scientific research is an innovative means to accomplish that end. We are only at the beginning to see what this new type of funding will mean for science.

Press contact: Alexander Lucaci, Alexander.Lucaci@emc2.foundation

About the Einsteinium Foundation:
The Einsteinium Foundation is an official Non-Profit Organization (NPO), and the world's first NPO to be backed by cryptocurrency. The defining characteristics of the Einsteinium Foundation are its ongoing commitment to research and charitable missions throughout the world, and to the safeguarding, maintenance, and development of Einsteinium, an international digital currency built on a secure, decentralized open ledger, or blockchain.

The 50 000 EMC2 were sent
txid: 1c6f49eb78a18630eec35fd1ecf7fc0910c6970407f4cf717d22511ed2c55901
Keep us updated on your research Grin